A Phase II Study of Dasatinib in Patients with Chemo-sensitive Relapsed Small Cell Lung Cancer (CALGB 30602)
- Citation:
- J Thorac Oncol vol 4 (9, suppl 1) S816, abstract P2.212
- Meeting Instance:
- IASLC (WCLC) 2009
- Year:
- 2009
- Type:
- Abstract
- Sub type:
- Poster General
- Funding:
- NCTN
- Endpoint:
- Primary
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- ppub
- Note:
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- No
- Parents:
- None
- Children:
- 198
- Program:
- OGC
- Primary Committee:
- Respiratory
- Sec. Committees:
- Pharmas:
- Grants:
- CA03927, CA114558-02, CA11789, CA31946, CA31983, CA32291, CA33601, CA35113, CA35279, CA41287, CA45418, CA45808, CA47642, CA77298, CA77406, CA77597, CA77658, CA86726, U10 CA031946-28, U10 CA033601
- Corr. Author:
- Authors:
- Antonius A. Miller Herbert Pang Lydia Hodgson Nithya Ramnath Gregory A. Otterson Michael J. Kelley Robert A. Kratzke Everett E. Vokes
- Networks:
- Study
- CALGB-30602
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 2
- Keywords:
- Phase II, Dasatinib, Small cell lung cancer